A Look At Insider Reactions To Teva Pharmaceutical Industries Limited (TEVA)

0
9

As of Wednesday close, Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) stock was down -$0.17, moving down -1.90 percent to $8.80. The average number of shares traded per day over the past five days has been 7,696,700 shares. 3 times new highs have been achieved over the past 5 days, with a -$0.10 fall in that time frame. In the last twenty days, the average volume was 10,590,200, while in the previous 50 days, it was 9,288,420.

Since last month, TEVA stock rose 2.68%. Shares of the company fell to $7.95 on 11/04/22, the lowest level in the past month. A 52-week high of $11.34 was reached on 08/11/22 after having rallying from a 52-week low of $6.78. Since the beginning of this year, TEVA’s stock price has risen by 9.86% or $0.79, and marked a new high 19 times. However, the stock has declined by -22.40% since its 52-week high.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


TEVA stock investors should be aware that Teva Pharmaceutical Industries Limited (TEVA) stock had its last reported insider trading activity 95 days ago on Aug 22. Kalif Eliyahu Sharon, the EVP, Chief Financial Officer of the company, disposed of 55,500 shares for $10.07 on Aug 22. It resulted in a $558,696 divestment by the insider. Stark David Matthew sold 58,163 shares at an average price of $9.04 on Jul 28. The insider now owns 2,974 shares following the transaction. On May 17, Executive VP, Global R&D Fridriksdottir Hafrun sold 130,000 shares at $8.22 apiece. The transaction was valued at $1,068,067.

Valuation Metrics

The stock’s beta is 1.27. Besides these, the trailing price-to-sales (P/S) ratio of 0.65, the price-to-book (PB) ratio of 1.12, and the price-to-cash flow ratio of 19.23 may also be considered.

The latest dividend of $0.0850 per share was paid out, remained unchanged from last year’s $0.0850.

Financial Health

In the three months ended September 29, Teva Pharmaceutical Industries Limited’s quick ratio stood at 0.70, while its current ratio was 1.00, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 2.11, and the total debt-to-equity ratio was 2.43. On the profitability front, the trailing twelve-month gross margin is 49.30% percent. In the year ended September 29, EBITDA margin amounted to 27.75%, whereas operating margins totaled -7.70%. Based on annual data, TEVA earned $7.59 billion in gross profit and brought in $15.88 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 4.50%. Return on equity (ROE) for the past 12 months was -13.80%.

In Teva Pharmaceutical Industries Limited’s quarter-end financial report for September 29, it reported total debt of $18.5 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. TEVA’s revenue fell -8.12% to $3.79 billion during the quarter, while net income inched up to $3.6 billion. While analysts expected Teva Pharmaceutical Industries Limited to report $0.62 quarterly earnings, the actual figure was $0.59 per share, beating the consensus estimate by -4.80%. During the quarter, the company generated $764.0 million in EBITDA. The liabilities of Teva Pharmaceutical Industries Limited were 34.73 billion at the end of its most recent quarter ended September 29, and its total debt was $21.62 billion. The value of shareholders’ equity is $1.11 billion.

Technical Picture

This quick technical analysis looks at Teva Pharmaceutical Industries Limited’s (TEVA) price momentum. With a historical volatility rate of 36.40%, the RSI 9-day stood at 46.94% on 23 November.

With respect to its five-day moving average, the current Teva Pharmaceutical Industries Limited price is down by -1.12% percent or -$0.10. At present, TEVA shares trade +1.03% above its 20-day simple moving average and +14.14% percent above its 100-day simple moving average. However, the stock is currently trading approximately -1.57% below its SMA50 and +6.15% above its SMA200.

Stochastic coefficient K was 54.24% and Stochastic coefficient D was 51.02%, while ATR was 0.38. Given the Stochastic reading of 50.30% for the 14-day period, the RSI (14) reading has been calculated as 49.47%. As of today, the MACD Oscillator reading stands at -0.12, while the 14-day reading stands at -0.12.

Analyst Ratings

Teva Pharmaceutical Industries Limited downgraded its rating on Teva Pharmaceutical Industries Limited (NYSE: TEVA) to an Underweight in a note to investors on November 14, 2022. The analysts firm previously had a Neutral rating on the stock.Teva Pharmaceutical Industries Limited (TEVA) has been rated Hold by analysts. According to 3 brokerage firms, TEVA is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Teva Pharmaceutical Industries Limited stock as buy, with 2 recommending it as overweight.

With a median target price of $10.00, the current consensus forecast for the stock is $7.00 – $13.00. Based on these forecasts, analysts predict Teva Pharmaceutical Industries Limited (TEVA) will achieve an average price target of $9.78.

LEAVE A REPLY

Please enter your comment!
Please enter your name here